此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

在接受放射治疗的肺癌患者中,超极化XENON-129磁共振成像用于研究辐射反应和毒性

2026年11月9日 更新者:M.D. Anderson Cancer Center

The goal of this clinical research study is to learn if novel type of imaging scan called HP 129Xe MRI can help doctors identify and predict common side effects of radiation therapy. Rather than contrast-enhanced MRIs, the tracer (129Xe) will be inhaled rather than injected.

The 129Xe tracer has not been FDA approved. Its use in this study is investigational.

研究概览

地位

招聘中

条件

详细说明

Primary Objectives:

To assess the association between imaging features on longitudinal HP 129Xe MRI and the development and severity of radiation pneumonitis resulting from radiation therapy for non-small cell lung cancer.

To determine if HP 129Xe MRI features, in conjunction with a given patient's radiation treatment plan, can predict radiation pneumonitis development and severity.

Secondary Objectives:

Optimize HP 129Xe MRI acquisition techniques.

To determine if HP 129Xe MRI can pre-emptively detect radiation pneumonitis prior to symptom presentation.

Compare changes in HP 129Xe MRI metrics to CT-based ventilation metrics over the course of radiation therapy.

To identify pulmonary regions more susceptible to radiation damage.

To develop alternative radiation treatment plans, based on HP 129Xe MRI features of lung function, that may prevent radiation pneumonitis development and compare to standard-of-care treatment plans.

研究类型

观察性的

注册 (估计的)

70

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • Texas
      • Houston、Texas、美国、77030
        • 招聘中
        • The University of Texas M. D. Anderson Cancer Center
        • 接触:
        • 首席研究员:
          • Joshua Niedzielski, PHD

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

是的

有资格学习的性别

全部

取样方法

非概率样本

研究人群

MD Anderson Cancer Center Participants

描述

Inclusion Criteria:

  1. Healthy control cohort:

    1. Able to consistently hold breath for 10-12 seconds
    2. No history of any pulmonary disorders (i.e., asthma, COPD, lung cancer, etc.)
    3. Able to undergo MRI examination
    4. At least 18 years of age
  2. Lung cancer patient cohort:

    1. Biopsy proven diagnosis of lung cancer
    2. Receiving photon- or proton-based external beam radiotherapy as a part of treatment
    3. Able to undergo MRI examination
    4. Will receive follow-up at University of Texas MD Anderson Cancer Center (UTMDACC)
    5. Able to consistently hold breath for 10-12 seconds
    6. Women and men with child-bearing potential agree to use adequate contraception prior to study entry and during the duration of study participation.
    7. Able to understand and willing to sign a written informed consent document
    8. At least 18 years of age

The effects of HP 129Xe MRI on the developing human fetus are unknown. For this reason and because radiotherapy is known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. (Refer to Pregnancy Assessment Policy MD Anderson Institutional Policy # CLN1114). This includes all female patients, between the onset of menses (as early as 8 years of age) and 55 years unless the patient presents with an applicable exclusionary factor which may be one of the following:

  • Postmenopausal (no menses in greater than or equal to 12 consecutive months).
  • History of hysterectomy or bilateral salpingo-oophorectomy.
  • Ovarian failure (Follicle Stimulating Hormone and Estradiol in menopausal range, who have received Whole Pelvic Radiation Therapy).
  • History of bilateral tubal ligation or another surgical sterilization procedure.
  • Approved methods of birth control are as follows: Hormonal contraception (i.e. birth control pills, injection, implant, transdermal patch, vaginal ring), Intrauterine device (IUD), Tubal Ligation or hysterectomy, Subject/Partner post vasectomy, Implantable or injectable contraceptives, and condoms plus spermicide. Not engaging in sexual activity for the total duration of the trial and the drug washout period is an acceptable practice; however periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of birth control. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Additionally, if female partners of male study participants become pregnant during study participation, the treating physician should be informed immediately.
  • Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

  1. Patients unable to follow up at MD Anderson for routine clinical care
  2. Inability or unwillingness to give informed consent
  3. Relapsed disease or life expectancy less than 6 months at time of enrollment
  4. Severe claustrophobia precluding MRI imaging active pulmonary infection
  5. Pregnant women
  6. Under 18 years of age

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 观测模型:CASE_CONTROL
  • 时间观点:PROSPECTIVE

队列和干预

团体/队列
干预/治疗
Arm A: High-Risk RP Patients

Gas delivery will be from a Tedlar bag

Arm B: Low-Risk RP Patients

Gas delivery will be from a Tedlar bag

Arm C: Healthy Volunteers (Negative Control)

Gas delivery will be from a Tedlar bag

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Safety and Adverse Events (AEs)
大体时间:Through study completion; an average of 1 year

Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0

Through study completion; an average of 1 year

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Joshua Niedzielski、M.D. Anderson Cancer Center

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年3月31日

初级完成 (估计的)

2028年9月1日

研究完成 (估计的)

2030年9月1日

研究注册日期

首次提交

2025年3月27日

首先提交符合 QC 标准的

2025年3月27日

首次发布 (实际的)

2025年4月3日

研究记录更新

最后更新发布 (实际的)

2026年11月12日

上次提交的符合 QC 标准的更新

2026年11月9日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

其他研究编号

  • 2024-1200
  • NCI-2025-02425 (其他标识符:NCI-CTRP Clinical Registry)

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅